De novo or recurrent glomerulonephritis and acute tubulointerstitial nephritis after COVID-19 vaccination: A report of six cases from a single center

Schaubschlager, Taylor; Rajora, Nilum; Diep, Sandy; Kirtek, Timothy; Cai, Qiuyin; Hendricks, Allen R.; Shastri, Shani; Zhou, Xin; Saxena, Ramesh

doi:10.5414/cn110794

Cited by 17 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Fever, headache None Urinalysis results normalized. 30 37 35 N/A F Relapse Pfizer Second N/A N/A, 0.36 g/gCr, 88.4 μmol/L Bland urine, 2 g/gCr, 99.9 μmol/L N/A Oral prednisolone, Mycophenolate Mofetil Four weeks later, proteinuria decreased to 1.143 mg/gCr and serum creatinine remained stable at 97.2 μmol/L 31 38 50 N/A M Initial onset Pfizer First None Negative hematuria by dipstick test, negative proteinuria by dipstick test, 79.6 μmol/L 10/HPF, 2+ proteinuria by dipstick test, 79.6 μmol/L Purpuric rashes RAASi After 100 days first vaccination, proteinuria decreased to 0.5 g/day. 32 39 50 N/A M Relapse Pfizer First 3 days N/A, 0.7 g/day, 88.4 μmol/L 170/μL, 329 g/mol (albumin), 106.1 μmol/L N/A N/A N/A 13 40 15 Asian M Initial onset Pfizer Second 1 day N/A, N/A, N/A 3+ hematuria by dipstick test, 3+ proteinuria by dipstick test, 85.7 μmol/L …”

Section: Resultsmentioning

confidence: 99%

“…As this is not a controlled study, we cannot conclude a causal relationship between COVID-19 vaccination and IgAN. However, COVID-19 vaccination is known to be associated with new onset and recurrence of glomerular disease due to its potent immunomodulatory effects, and various therapeutic effects have been reported [ [7] , [9] , [11] , [12] , [15] , [21] , [26] , [27] , [28] , [31] , [32] , [34] , [35] , [36] , [37] , [38] , [40] ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

IgA nephropathy after COVID-19 vaccination and analysis of reported cases

Mima

Lee

2023

Heliyon

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

IgA nephropathy after COVID-19 vaccination and analysis of reported cases

Mima

Lee

2023

Heliyon

View full text Add to dashboard Cite

“…IgA nephropathy is the most common GN after receiving the mRNA COVID-19 vaccine, followed by minimal change disease [ 8 – 10 ]. In the literature, 47 cases of IgA nephropathy following mRNA COVID-19 vaccination have been reported (30 de novo and 17 flare-ups) thus far [ 3 , 9 – 40 ]. Gross hematuria within 1–2 days after vaccination was the most common initial presentation, followed by acute kidney injury.…”

Section: Discussionmentioning

confidence: 99%

IgA vasculitis presenting as nephrotic syndrome following COVID-19 vaccination: a case report

Cho

Kim

2022

BMC Nephrol

View full text Add to dashboard Cite

Background Following the strong recommendation for coronavirus disease 2019 (COVID‑19) vaccination, many patients with medical comorbidities are being immunized. However, the safety of vaccination in patients with autoimmune diseases has not been well established. We report a new case of biopsy-proven IgA vasculitis with nephritis presenting as a nephrotic syndrome after mRNA COVID-19 vaccination in a patient with a history of leukocytoclastic vasculitis. Case presentation A 76-year-old man with a history of cutaneous leukocytoclastic vasculitis presented with purpura in both lower limbs, followed by nephrotic syndrome after the second dose of BNT162b2 mRNA COVID-19 vaccination. Skin and renal biopsy revealed IgA vasculitis with nephritis. The patient’s past medical history of leukocytoclastic vasculitis and features of chronicity in renal pathology suggest an acute exacerbation of preexisting IgA vasculitis after COVID-19 vaccination. After the steroid and renin-angiotensin system inhibitor use, purpura and acute kidney injury recovered within a month. Subnephrotic proteinuria with microscopic hematuria remained upon follow-up. Conclusion Physicians should keep in mind the potential (re)activation of IgA vasculitis following mRNA COVID-19 vaccines. It is important to closely monitor COVID-19 vaccinated patients, particularly those with autoimmune diseases.

show abstract

“…Reports of de novo and relapses of glomerular disease (GD) temporally associated with COVID-19 vaccination (termed CVAGD for COVID-19 vaccine–associated GD) began to emerge by mid-2021 with an increasing number of reports published. 2-27 To date, a cause-effect relationship has not been established. Given the relative rarity of these events and limited follow-up, we created an International Registry of COVID-19 vaccination and Glomerulonephritis to collect consistent data on potential cases of CVAGD to analyze in aggregate.…”

Section: Introductionmentioning

confidence: 99%

COVID-19 Vaccination and New Onset Glomerular Disease: Results from the IRocGN2 International Registry

Waldman¹,

Sinaii

Lerma

et al. 2023

Kidney360

View full text Add to dashboard Cite

Background:Cases of de novo glomerular disease with various renal histologies have been reported after vaccination against SARS-CoV-2. Causality has not been established and the long-term outcomes are not known. To better characterize the glomerular diseases and clinical course/outcomes, we created the International Registry of COVID-19 vaccination and Glomerulonephritis (IRocGN2) to study in aggregate de novo glomerulonephritis cases suspected after COVID-19 vaccine exposure Methods:A RedCap survey was used for anonymized data collection. Detailed information on vaccination type and timing and glomerular disease histology were recorded in the registry. We collected serial information on laboratory values (before and after vaccination and during follow-up), treatments, and kidney-related outcomes. Results: Ninety-eight glomerular disease cases were entered into the registry over eleven months from 44 centers throughout the world. Median follow-up was 89 days after diagnosis. IgA nephropathy (IgAN) and minimal change disease (MCD) were the most the common kidney diseases reported. Recovery of kidney function and remission of proteinuria was more likely in IgAN and MCD at 4-6 months than with pauci immune glomerulonephritis /vasculitis and membranous nephropathy. Conclusions:Development of glomerular disease after vaccination against SARS-CoV-2 may be a very rare adverse event. Temporal association is present for IgAN and MCD, but causality is not firmly established. Kidney outcomes for IgAN and MCD are favorable. No changes in vaccination risk-benefit assessment is recommended based on these findings.

show abstract

De novo or recurrent glomerulonephritis and acute tubulointerstitial nephritis after COVID-19 vaccination: A report of six cases from a single center

Cited by 17 publications

References 0 publications

IgA nephropathy after COVID-19 vaccination and analysis of reported cases

IgA nephropathy after COVID-19 vaccination and analysis of reported cases

IgA vasculitis presenting as nephrotic syndrome following COVID-19 vaccination: a case report

COVID-19 Vaccination and New Onset Glomerular Disease: Results from the IRocGN2 International Registry

Contact Info

Product

Resources

About